Clearmind Medicine (STU:CWY0) EPS (Basic): €-160.55 (TTM As of Apr. 2026)


STU:CWY0 Clearmind Medicine Inc STU:CWY0
22 GF Score
Price €26.00
! 1 Warning Sign
View Full Analysis

What is Clearmind Medicine EPS (Basic)?

Clearmind Medicine STU:CWY0 22 EPS (Basic) is €-160.55 as of Apr. 2026. GuruFocus rates STU:CWY0 with a GF Score™ of 22/100. The stock has 1 warning sign investors should review.

Clearmind Medicine's basic earnings per share (Basic EPS) for the three months ended in Apr. 2026 was €-5.80. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Apr. 2026 was €-160.55.

Clearmind Medicine's EPS (Diluted) for the three months ended in Apr. 2026 was €-5.80. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Apr. 2026 was €-160.55.

Clearmind Medicine's EPS without NRI for the three months ended in Apr. 2026 was €-5.79. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Apr. 2026 was -214.63.

During the past 3 years, the average EPS without NRI Growth Rate was 81.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was -16.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 9 years, Clearmind Medicine's highest 3-Year average EPS without NRI Growth Rate was 81.00% per year. The lowest was -733.60% per year. And the median was -95.00% per year.

Clearmind Medicine  (STU:CWY0) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Clearmind Medicine EPS (Basic) Related Terms

Clearmind Medicine EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Clearmind Medicine's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clearmind Medicine EPS (Basic) Chart

Clearmind Medicine Annual Data
Trend Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only -22,588.45 -64,204.51 -5,378.09 -622.40 -260.71

Clearmind Medicine Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -55.42 -85.70 -40.80 -28.25 -5.80
STU:CWY0
22GF Score
Clearmind Medicine Inc STU:CWY0
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clearmind Medicine EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Clearmind Medicine's Basic EPS for the fiscal year that ended in Oct. 2025 is calculated as

Basic EPS (A: Oct. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-3.313-0)/0.013
=-254.85

Clearmind Medicine's Basic EPS for the quarter that ended in Apr. 2026 is calculated as

Basic EPS (Q: Apr. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-1.751-0)/0.302
=-5.80

EPS (Basic) for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-160.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of €-160.55 mean?
Clearmind Medicine (STU:CWY0) has a EPS (Basic) of €-160.55 as of Apr. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Clearmind Medicine and its competitors.
Is Clearmind Medicine's EPS (Basic) too high?
Clearmind Medicine's current EPS (Basic) is €-160.55. Overall, Clearmind Medicine has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Clearmind Medicine's EPS (Basic) compare to BIXT and GRI?
Clearmind Medicine's EPS (Basic) of €-160.55 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Clearmind Medicine and its competitors. Clearmind Medicine's current EPS (Basic) is €-160.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clearmind Medicine stock overvalued right now?
Clearmind Medicine (STU:CWY0) has a current EPS (Basic) of €-160.55. The current EPS (Basic) is €-160.55. Clearmind Medicine's overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Clearmind Medicine (STU:CWY0), the current EPS (Basic) is €-160.55 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Clearmind Medicine Business Description

Other Exchanges CMND:USA
Address 101-1220 West 6th Avenue, Vancouver, BC, CAN, V6H1A5
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.
22GF Score

Get the complete analysis for STU:CWY0

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€26.00
Price